Skip to main content

Table 2 Clinical characteristics of the patients with IgAN according to disease progression

From: Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy

 

Progression

(n = 21)

Non-progression

(n = 170)

P

Age, years

53.3 ± 15.4

40.0 ± 14.4

0.001

Male, n (%)

11 (52.4)

74 (43.5)

0.44

HTN, n (%)

16 (76.2)

61 (35.9)

< 0.001

DM, n (%)

2 (9.5)

9 (5.3)

0.43

BMI, kg/m2

24.3 ± 3.3

23.9 ± 3.3

0.42

Albumin, g/dL

3.7 ± 0.4

3.9 ± 0.6

0.01

IgA, mg/dL

336.6 ± 88.5

304.5 ± 104.9

0.07

eGFR, ml/min/1.73 m2

55.9 ± 34.9

86.9 ± 32.7

< 0.001

Urine PCR, g/gCr

2.7 ± 2.3

1.4 ± 1.8

< 0.001

Use of ARB or ACEi, n (%)

16 (76.2)

124 (72.9)

0.75

Use of immunosuppressant, n (%)

12 (57.1)

101 (59.4)

0.84

Oxford classification M

  

0.76

0

11 (52.4)

95 (55.9)

 

1

10 (47.6)

75 (44.1)

 

Oxford classification E

  

0.68

0

16 (76.2)

136 (80.0)

 

1

5 (76.9)

34 (20.0)

 

Oxford classification S

  

0.80

0

13 (61.9)

110 (64.7)

 

1

8 (38.1)

60 (35.3)

 

Oxford classification T

  

0.96

0

18 (85.7)

145 (85.3)

 

1, 2

3 (14.3)

25 (14.7)

 

Oxford classification C

  

0.92

0

17 (81.0)

145 (85.3)

 

1, 2

4 (9.0)

24 (14.7)

 
  1. ARB, angiotensin II receptor blockers; ACEi, angiotensin II converting enzyme inhibitors; BMI, body mass index; C, crescents; DM, diabetes mellitus; E, endocapillary hypercellularity; eGFR, estimated glomerular filtration rate; HPF, high-power field; HTN, hypertension; M, mesangial hypercellularity; PCR, protein–creatinine ratio; RBC, red blood cell; S, segmental glomerulosclerosis; T, interstitial fibrosis/tubular atrophy
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us